Dallas, Texas 07/21/2015 (Financialstrend) – Eli Lilly and Co (NYSE:LLY) finds itself in a tight spot ahead of the release of clinical results for its drug Solanezumab, intended for Alzheimer treatment. The outcome of the trial will have a huge bearing on whether the drug will be the first to be marketed as a treatment for slowing progression of the Alzheimer disease.
Eli Lily Up ON Alzheimer Drug Prospects
A lot is at stake with the release as the Alzheimer program has made Eli Lilly and Co (NYSE:LLY) trade more as a biotechnology company than a pharmaceutical company. The company is also struggling with the expiration of patents of some of its lead drugs calling for new blockbusters to sustain earnings. The excitement around the Alzheimer program has seen the stock soar by 40% over the past one year and up by 20% against a relatively flat pharmaceutical sector.
The fact that more than 5.3 million suffer from Alzheimer in the US alone provides a good market for Eli Lilly and Co (NYSE:LLY) upon favorable results and approval. The number could triple by 2050 providing a huge marketplace for the drug as currently approved treatments only address symptoms rather than slow the disease progression.
Annual Sales of $3 Billion Looming
A huge market opportunity awaits a drug that can slow the progression of the disease and even if it will be limited to a set of patients, it is sure to become a blockbuster. Jeffrey Holford, an analyst at Jefferies & Co, believes Eli Lilly and Co (NYSE:LLY)’s drug upon approval could generate peak annual sales of up to $3 billion.
Positive results from the ongoing clinical trial should bolster the stock’s sentiments on the Street and more so bolster its outlook in terms of favorable sales and earnings. However, the drug also poses risks to the stock as previous studies have only amounted to negative results. The odds of success are still daunting and may come to haunt the stock should the results fail to meet expectations.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.